MS FIRST - utilising a longitudinal, prospective, comparative drug safety module for use in everyday MS clinical practice to evaluate and track incidence and characteristics of safety outcomes in MS patients on therapy over the long term

J. Haartsen, T. Spelman, J. Baker, S. Agland, J. Lechner-Scott, T. Burke, S. Vucic, L. Rath, O. Skibina, M. Toubia, M. Slee, B. Taylor, S. Mac Gregor, A. M. Oconnell, M. Barnett, S. Baker, M. Sharma, S. Hodgkinson, S. Walters, A. KermodeW. Hayes, E. Butler, N. Sheuy, C. Shaw, R. Portley, T. Hardy, I. L. Tan, H. Butzkueven

Research output: Contribution to journalAbstract/Meeting Abstract

29 Citations (Scopus)
Original languageEnglish
Pages (from-to)403-404
Number of pages2
JournalMultiple Sclerosis Journal
Volume23
Publication statusPublished - Oct 2017
Event7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS) - Paris, France
Duration: 25 Oct 201728 Oct 2017

Cite this

Haartsen, J., Spelman, T., Baker, J., Agland, S., Lechner-Scott, J., Burke, T., Vucic, S., Rath, L., Skibina, O., Toubia, M., Slee, M., Taylor, B., Mac Gregor, S., Oconnell, A. M., Barnett, M., Baker, S., Sharma, M., Hodgkinson, S., Walters, S., ... Butzkueven, H. (2017). MS FIRST - utilising a longitudinal, prospective, comparative drug safety module for use in everyday MS clinical practice to evaluate and track incidence and characteristics of safety outcomes in MS patients on therapy over the long term. Multiple Sclerosis Journal, 23, 403-404.